CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
Sponsor
Henry Ford Health System (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05718791
Collaborator
(none)
100
1
37
2.7
Study Details
Study Description
Brief Summary
The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
100 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
CXC-chemokine Ligand 9 (CXCL9) and Endothelial Activation and Stress Index (EASIX) for Prediction of Acute Graft Versus Host Disease
Anticipated Study Start Date
:
Mar 1, 2023
Anticipated Primary Completion Date
:
Mar 30, 2026
Anticipated Study Completion Date
:
Mar 30, 2026
Outcome Measures
Primary Outcome Measures
- predictors of acute GVHD [CXCL9 combined with EASIX calculated at day 28 +/- 2 post SCT can be used as predictors of acute GVHD by day 100.]
CXCL9 combined with EASIX can be used as predictors of acute GVHD
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 80 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
- Patients >18 year old admitted for allo SCT PB for malignant disease.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Henry Ford Health System | Detroit | Michigan | United States | 48202 |
Sponsors and Collaborators
- Henry Ford Health System
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Shatha Farhan,
Clinical Assistant Professor,
Henry Ford Health System
ClinicalTrials.gov Identifier:
NCT05718791
Other Study ID Numbers:
- hhf
First Posted:
Feb 8, 2023
Last Update Posted:
Feb 8, 2023
Last Verified:
Jan 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: